IVROSE JANVIER: Open Payments
NPI 1821134453 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,106 in 32 payments from 15 companies in 2025. Trend: 2023 $663 · 2024 $1,188 · 2025 $1,106
Food & beverage: $1,106
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 1 | $121 |
| ABIOMED | 1 | $118 |
| MEDICOMP INC | 3 | $117 |
| Esperion Therapeutics, Inc. | 4 | $97 |
| Merck Sharp & Dohme LLC | 5 | $91 |
| BIOTRONIK INC. | 1 | $89 |
| Novartis Pharmaceuticals Corporation | 3 | $83 |
| Abbott Laboratories | 1 | $81 |
| Novo Nordisk Inc | 3 | $74 |
| BridgeBio Pharma, Inc. | 3 | $71 |
Products named: TELEPATCH CARDIAC MONITOR, NEXLETOL, VERQUVO, BIOMONITOR, LEQVIO, CARDIOMEMS, Ozempic, Attruby.
Industry payments across NY — which companies pay providers there.
